Solventum Beats Q1 Targets, Raises EPS Outlook as Turnaround Gains Traction
Solventum (SOLV) posted a solid beat in its first-quarter earnings report on Tuesday, signaling that the healthcare spin-off's multiyear transformation is gaining real momentum. Executives pointed to strong volume-driven growth across all three segments, early wins from the Acera acquisition, and a clearer path to margin expansion—even as the company navigates tariff headwinds and the final stages of its complex separation from 3M.
Speaking on the earnings call, CEO Bryan Hanson credited the company's global workforce—dubbed "Solvers"—for delivering results amid a fast-paced restructuring environment. “This team’s ability to drive outcomes while navigating ongoing separation efforts, ERP implementations, and acquisitions and divestitures is a testament to the strong talent we have in the organization,” he said.
Solventum reported organic sales growth of 2.1% for the quarter, with total revenue reaching $2 billion. On a normalized basis—stripping out SKU rationalization impacts, separation-related timing shifts, and the Acera contribution—organic growth was approximately 4%. Adjusted earnings per share came in at $1.48, up 11% year-over-year and ahead of consensus expectations.
The company’s adjusted operating margin landed at 19.5%, supported by favorable mix, programmatic savings, and portfolio moves. Gross margins improved 80 basis points to 56.4%, even as tariff-related costs weighed on the quarter. CFO Wayde McMillan noted that the company is holding its full-year tariff headwind estimate at $100 million to $120 million, with no refunds yet recognized.
Segment Performance and Strategic Progress
MedSurg, Solventum’s largest segment, posted $1.2 billion in sales, with Advanced Wound Care growing 2.1%. The recently acquired Acera contributed $28 million in revenue and is already being integrated into the company’s advanced wound care infrastructure. Infection Prevention and Surgical Solutions grew 0.6%, while Dental Solutions rose 3.4%, driven by strong demand for new products like Filtek EasyMatch and Clarity Aligners Pro Clear.
Health Information Systems delivered $342 million in sales, up 4.7%, fueled by strength in revenue cycle management and autonomous coding. Hanson emphasized that AI is a tool, not a silver bullet: “What differentiates the outcomes is the data, the rules, and the rigor behind them.” The company now expects that 80% to 90% of all coding could eventually become fully autonomous, with a target of moving nearly half its customers to autonomous coding within the current strategic plan period.
On the operational front, Solventum has exited roughly 50% of its transition service agreements with 3M and migrated 75% of over 1,200 system applications. The next major milestone is the U.S. and Canada ERP cutover in Q3, which the company expects to be the last large-scale migration. To mitigate disruption, Solventum is planning over $100 million in advanced orders to distributors in Q2, which will be reversed later in the year.
Capital Allocation and Portfolio Optimization
Solventum repurchased approximately 923,000 shares in Q1 for $67 million, part of a $1 billion buyback program authorized by the board. McMillan described the capital plan as “balanced,” with room for both share repurchases and tuck-in acquisitions. “We see portfolio optimization as a perpetual lever for value creation,” Hanson said, noting that the company is actively assessing its businesses for strategic and financial fit.
The company also highlighted progress on its Transform for the Future program, a multiyear $500 million savings initiative aimed at streamlining systems, increasing automation, and optimizing the global footprint. Hanson said the program is already paying dividends and will deliver more meaningfully in 2027 and beyond.
Market Reaction and Analyst Questions
Analysts on the call pressed for clarity on the Q2 phasing dynamics tied to the ERP cutover. McMillan advised against adjusting quarterly models, noting that the company will disclose the exact amount of advanced orders after Q2 and adjust the back half accordingly. “Do not change your Q2 models,” he said. “When Q2 happens, we will disclose the phasing amount, and we will mirror that out of the second half.”
When asked about the sustainability of momentum, Hanson was unequivocal: “It is not a question of whether we get to our LRP targets of 4% to 5% organic sales growth; it is a question of when.”
Industry Perspectives
Maria Torres, a healthcare equity analyst at a mid-sized asset manager, said: “Solventum is executing well on the operational side, but the real test will be whether they can sustain this momentum through the ERP cutover in Q3. The advanced ordering strategy is smart, but it creates noise in the quarterly numbers. I’m watching the margin trajectory more closely—if they can hold 21% operating margins for the full year despite tariffs, that would be a strong signal.”
James Kowalski, a former medical device executive turned consultant, was more skeptical: “Look, they’re doing a lot of financial engineering—buybacks, SKU cuts, selling off businesses—but where’s the organic growth? They’re still barely above 2% on a reported basis. The LRP targets are aspirational at best. I’ve seen this movie before: a spin-off talks a big game, loads up on buybacks, and then misses the numbers. I’ll believe it when I see it.”
Linda Chen, a portfolio manager focused on mid-cap healthcare, offered a measured take: “The Acera acquisition is a good example of the kind of bolt-on deal that makes sense—high growth, adjacent to existing capabilities, and immediately accretive. The autonomous coding story is also compelling. But the tariff overhang and the ERP risk are real. I’m cautiously optimistic, but I need to see a few more quarters of consistent execution before I get more aggressive.”
Outlook
Solventum maintained its full-year organic sales growth and free cash flow guidance, while raising its EPS outlook to the high end of the $6.40 to $6.60 range. The company expects operating margins of 21% to 21.5% for the year, an improvement of 50 to 100 basis points over 2025. Free cash flow is expected to improve through the year, with Q4 being the strongest quarter.
“We are well on our way to delivering our 2026 guidance and, importantly, our go-forward LRP objectives,” Hanson said. “Our transformation journey is working.”
This article is based on Solventum’s Q1 2026 earnings call and related materials. The Motley Fool has a disclosure policy.